Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash & Equivalents: 2017-2024

Historic Cash & Equivalents for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $189.8 million.

  • Cidara Therapeutics' Cash & Equivalents rose 130.52% to $293.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $293.7 million, marking a year-over-year increase of 130.52%. This contributed to the annual value of $189.8 million for FY2024, which is 430.56% up from last year.
  • According to the latest figures from FY2024, Cidara Therapeutics' Cash & Equivalents is $189.8 million, which was up 430.56% from $35.8 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Cash & Equivalents ranged from a high of $189.8 million in FY2024 and a low of $32.7 million during FY2022.
  • Over the past 3 years, Cidara Therapeutics' median Cash & Equivalents value was $35.8 million (recorded in 2023), while the average stood at $86.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 45.16% in 2022, then soared by 430.56% in 2024.
  • Yearly analysis of 5 years shows Cidara Therapeutics' Cash & Equivalents stood at $35.9 million in 2020, then surged by 66.18% to $59.7 million in 2021, then crashed by 45.16% to $32.7 million in 2022, then increased by 9.31% to $35.8 million in 2023, then skyrocketed by 430.56% to $189.8 million in 2024.